Antimicrobial, anti-inflammatory, wound-healing glass powder and use thereof
Abstract
The invention relates to an anti-inflammatory, wound-healing glass powder, whereby the glass of the glass powder comprises the following components: 20-80 wt. % SiO2, 0-40 wt. % Na2O, 0-40 wt. % K2O, 0-40 wt. % Li2O, 0-40 wt. % CaO, 0-40 wt. % MgO, 0-40 wt. % Al2O3, 0-1 wt. % P2O5, 0-40 wt. % B2O3 and 0-10 wt. % ZnO.

Term
Term ended
Expired 17 August 2022, 4.1 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
25 claims: 25 independent, 0 dependent
- 1An anti-inflammatory and wound-healing glass powder, with the glass of the glass powder comprising the following components in weight percent on oxide basis:20 to 80% by weight of SiO20 to 40% by weight of Na2O0 to 40% by weight of K2O0 to 40% by weight of Li2O0 to 40% by weight of CaO0 to 40% by weight of MgO0 to 40% by weight of Al2O30% by weight of P2O50 to 40% by weight of B2O30 to 10% by weight of ZnO and optionally trace elements and/or usual refining agents in the usual quantities, with the sum total of Na2O + K2O + Li2O + CaO + MgO being 15 to 80% by weight, and the glass of the glass powder being free of Ag and the size of the glass particles of the glass powder being on average < 100 µm, preferably < 50 µm, more preferably < 20 µm. Entzündungshemmend und wundheilend wirkendes Glaspulver, wobei das Glas des Glaspulvers die nachfolgenden Komponenten in Gew-% auf Oxidbasis umfaßt: 20 - 80 Gew.-% SiO20 - 40 Gew.-% Na2O0 - 40 Gew.-% K2O0 - 40 Gew.-% Li2O0 - 40 Gew.-% CaO0 - 40 Gew.-% MgO0 - 40 Gew.-% Al2O30 Gew.-% P2O50 - 40 Gew.-% B2O30 - 10 Gew.-% ZnO und gegebenenfalls Spurenelementen und/oder übliche Läutermittel in üblichen Mengen, wobei die Summe Na2O + K2O + Li2O + CaO + MgO 15 bis 80 Gew.-% beträgt, und das Glas des Glaspulvers frei von Ag ist und die Größe der Glaspartikel des Glaspulvers im Mittel < 100 µm, bevorzugt < 50 µm, besonders bevorzugt < 20 µm ist. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant, caractérisée en ce que le verre de la poudre de verre contient les composants suivants, en pourcentage en poids sur la base de l'oxyde : 20 à 80 % en poids de SiO20 à 40 % en poids de Na2O0 à 40 % en poids de K2O0 à 40 % en poids de Li2O0 à 40 % en poids de CaO0 à 40 % en poids de MgO0 à 40 % en poids d'Al2O30 % en poids de P2O50 à 40 % en poids de B2O30 à 10 % en poids de ZnO et éventuellement des éléments traces et/ou les agents d'affinage habituels dans les quantités habituelles, et en ce que la somme de Na2O + K2O + Li2O + CaO + MgO représente 15 à 80 % en poids et le verre de la poudre de verre ne contient pas d'Ag et la taille des particules de verre de la poudre de verre est en moyenne < 100 µm, de préférence < 50 µm et en particulier < 20 µm.
- 2An anti-inflammatory and wound-healing glass powder according to claim 1, with the sum total of Na2O + K2O + Li2O being 5 to 50% by weight. Entzündungshemmendes und wundheilend wirkendes Glaspulver, nach Anspruch 1, wobei die Summe Na2O + K2O + Li2O 5 bis 50 Gew-% beträgt. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon la revendication 1, caractérisée en ce que la somme de Na2O + K2O + Li2O représente 5 à 50 % du poids.
- 3An anti-inflammatory and wound-healing glass powder according to claim 1, with the sum total of CaO + MgO being 5 to 50% by weight. Entzündungshemmendes und wundheilend wirkendes Glaspulver, nach Anspruch 1, wobei die Summe CaO + MgO 5 bis 50 Gew-% beträgt. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon la revendication 1, caractérisée en ce que la somme de CaO + MgO représente 5 à 50 % du poids.
- 4An anti-inflammatory and wound-healing glass powder, with the glass of the glass powder comprising the following components in weight percent on oxide basis:68 to 75% by weight of SiO210 to 20% by weight of Na2O5 to 15% by weight of CaO0 to 10% by weight of MgO0 to 3% by weight of Al2O30% by weight of P2O5 and optionally trace elements and/or usual refining agents in the usual quantities, and the size of the glass particles of the glass powder is on average < 100 µm, preferably < 50 µm, more preferably < 20 µm. Entzündungshemmend und wundheilend wirkendes Glaspulver, wobei das Glas des Glaspulvers die nachfolgenden Komponenten in Gew-% auf Oxidbasis umfaßt: 68 - 75 Gew.-% SiO210 - 20 Gew.-% Na2O5 - 15 Gew.-% CaO0 - 10 Gew.-% MgO0 - 3 Gew.-% Al2O30 Gew.-% P2O5 und gegebenenfalls Spurenelementen und/oder übliche Läutermittel in üblichen Mengen, und die Größe der Glaspartikel des Glaspulvers im Mittel < 100 µm, bevorzugt < 50 µm, besonders bevorzugt < 20 µm ist. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant, caractérisée en ce que le verre de la poudre de verre contient les composants suivants, en pourcentage en poids sur la base de l'oxyde : 68 à 75 % en poids de SiO210 à 20 % en poids de Na2O5 à 15 % en poids de CaO0 à 10 % en poids de MgO0 à 3 % en poids d'Al2O30 % en poids de P2O5 et éventuellement des éléments traces et/ou les agents d'affinage habituels dans les quantités habituelles, caractérisée en ce que la taille des particules de verre de la poudre de verre est en moyenne < 100 µm, de préférence < 50 µm et en particulier < 20 µm.
- 5An anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 4, with the glass of the glass powder further comprising 0 to 30% by weight of XFy, wherein X may be Li, Na, K, Be, Mg, Ca and y=1 or y=2. Entzündungshemmend und wundheilend wirkendes Glaspulver gemäß einem der Anspruche 1 bis 4, wobei das Glas des Glaspulvers desweiteren 0 - 30 Gew.-% XFy, wobei X Li, Na, K, Be, Mg, Ca sein kann und y=1 oder y=2, umfaßt. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 4, caractérisée en ce que le verre de la poudre de verre contient en outre 0 à 30 % en poids de XFy, où X peut être Li, Na, K, Be, Mg, Ca et y = 1 ou y = 2.
- 6An anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 5, with the glass of the glass powder further comprising 0 to 10% by weight of XJy, wherein X may be Li, Na, K, Be, Mg, Ca and y=1 or y=2. Entzündungshemmend und wundheilend wirkendes Glaspulver gemäß einem der Ansprüche 1 bis 5, wobei das Glas des Glaspulvers des weiteren 0 - 10 Gew-% XJy, wobei X Li, Na, K, Be, Mg, Ca sein kann und y=1 oder y=2 umfaßt. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 5, caractérisée en ce que le verre de la poudre de verre contient en outre 0 à 10 % en poids de XJy, où X peut être Li, Na, K, Be, Mg, Ca et y = 1 ou y = 2.
- 7An anti-inflammatory and wound-healing glass powder, with the glass of the glass powder comprising the following components:20 to 80% by weight of Si020 to 30% by weight of Na2O0 to 30% by weight of K2O0 to 30% by weight of CaO0 to 30% by weight of MgO0 to 30% by weight of Al2O30% by weight of P2O50 to 40% by weight of B2O3 and optionally trace elements and/or usual refining agents in the usual quantities, and the glass of the glass powder is free of Ag and the size of the glass particles of the glass powder is on average < 100 µm, preferably < 50 µm, more preferably < 20 µm. Entzündungshemmend und wundheilend wirkendes Glaspulver, wobei das Glas des Glaspulvers die nachfolgenden Komponenten umfaßt: 20 - 80 Gew.-% SiO20 - 30 Gew.-% Na2O0 - 30 Gew.-% K2O0 - 30 Gew.-% CaO0 - 30 Gew.-% MgO0 - 30 Gew.-% Al2O30 Gew.-% P2O50 - 40 Gew.-% B2O3 und gegebenenfalls Spurenelemente und/oder übliche Läutermittel in üblichen Mengen und das Glas des Glaspulvers frei von Ag ist und die Größe der Glaspartikel des Glaspulvers im Mittel < 100 µm, bevorzugt < 50 µm, besonders bevorzugt < 20 µm ist. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant, caractérisée en ce que le verre de la poudre de verre contient les composants suivants, en pourcentage en poids sur la base de l'oxyde : 20 à 80 % en poids de SiO20 à 30 % en poids de Na2O0 à 30 % en poids de K2O0 à 30 % en poids de CaO0 à 30 % en poids de MgO0 à 30 % en poids d'Al2O30 % en poids de P2O50 à 40 % en poids de B2O3 et éventuellement des éléments traces et/ou les agents d'affinage habituels dans les quantités habituelles, et en ce que le verre de la poudre de verre ne contient pas d'Ag et la taille des particules de verre de la poudre de verre est en moyenne < 100 µm, de préférence < 50 µm et en particulier < 20 µm.
- 8An anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 7, characterized in that the glass of the glass powder further comprises heavy metal ions, chosen from the class of the following elements:Cu, Zn. Entzündungshemmend und wundheilend wirkendes Glaspulver nach einem der Ansprüche 1 bis 7 dadurch gekennzeichnet, daß das Glas des Glaspulvers desweiteren Schwermetallionen, ausgewählt aus der Klasse der nachfolgenden Elemente: Cu, Znumfaßt Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 7, caractérisée en ce que le verre de la poudre de verre contient en outre des ions de métaux lourds, sélectionnés dans la classe contenant les éléments : Cu, Zn.
- 9An anti-inflammatory and wound-healing glass powder according to one of the claims 4 to 6, characterized in that the glass of the glass powder further comprises Ag. Entzündungshemmend und wundheilend wirkendes Glaspulver nach einem der Ansprüche 4 bis 6, dadurch gekennzeichnet, daß das Glas des Glaspulvers des weiteren Ag umfasst. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 4 à 6, caractérisée en ce que le verre de la poudre de verre contient en outre de l'Ag.
- 10An anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 7, characterized in that the glass of the glass powder is free of heavy metals, especially not containing any Cu, Zn. Entzündungshemmend und wundheilend wirkendes Glaspulver nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, daß das Glas des Glaspulvers frei von Schwermetallen ist, insbesondere kein Cu, Zn enthält. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 4 à 6, caractérisée en ce que le verre de la poudre de verre ne contient pas de métaux lourds, et en particulier pas de Cu ni de Zn.
- 11An anti-inflammatory and wound-healing glass powder according to one of the claims 4 to 6, characterized in that the glass of the glass powder is free of Ag. Entzündungshemmend und wundheilend wirkendes Glaspulver nach einem der Ansprüche 4 bis 6, dadurch gekennzeichnet, daß das Glas des Glaspulvers frei von Ag ist. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 4 à 6, caractérisée en ce que le verre de la poudre de verre ne contient pas d'Ag.
- 12An anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 11, characterized in that the size of the particles of the glass powders is on average < 10 µm. Entzündungshemmendes und wundheilendes Glaspulver nach einem der Ansprüche 1 bis 11, dadurch gekennzeichnet, daß die Größe der Partikel des Glaspulvers im Mittel < 10 µm ist. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 11, caractérisée en ce que la taille des particules de la poudre de verre est en moyenne < 10 µm.
- 13An anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 11, characterized in that the size of the glass particles is < 5 µm. Entzündungshemmend und wundheilend wirkendes Glaspulver nach einem der Ansprüche 1 bis 11, dadurch gekennzeichnet, daß die Größe der Glaspartikel < 5 µm ist. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 11, caractérisée en ce que la taille des particules de la poudre de verre est en moyenne < 5 µm.
- 14An anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 11, characterized in that the size of the glass particles is on average < 1 µm. Entzündungshemmend und wundheilend wirkendes Glaspulver nach einem der Ansprüche 1 bis 11, dadurch gekennzeichnet, daß die Größe der Glaspartikel des Glaspulvers im Mittel < 1 µm ist. Poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 11, caractérisée en ce que la taille des particules de la poudre de verre est en moyenne < 1 µm.
- 15The use of an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 14 in cosmetic products. Utilisation d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 14 dans des cosmétiques. Verwendung eines entzündungshemmend und wundheilend wirkenden Glaspulvers nach einem der Ansprüche 1 bis 14 in Kosmetikprodukten.
- 16The use of an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 14 in deodorant products. Utilisation d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 14 dans des déodorants. Verwendung eines entzündungshemmend und wundheilend wirkenden Glaspulvers nach einem der Ansprüche 1 bis 14 in Deodorantprodukten.
- 17The use of an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 14 in medical products and preparations. Utilisation d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 14 dans des produits et préparations médicinaux. Verwendung eines entzündungshemmend und wundheilend wirkenden Glaspulvers nach einem der Ansprüche 1 bis 14 in medizinischen Produkten und Präparaten.
- 18The use of an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 16 in plastic material and polymers. Utilisation d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 16 dans des matières plastiques et de polymères. Verwendung eines entzündungshemmend und wundheilend wirkenden Glaspulvers nach einem der Ansprüche 1 bis 16 in Kunststoffen und Polymeren.
- 19The use of an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 14 in the area of paper hygiene. Utilisation d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 14 dans le domaine de l'hygiène du papier. Verwendung eines entzündungshemmend und wundheilend wirkenden Glaspulvers nach einem der Ansprüche 1 bis 14 im Bereich der Papierhygiene.
- 20The use of an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 14 in foodstuffs. Utilisation d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 14 dans des produits alimentaires. Verwendung eines entzündungshemmend und wundheilend wirkenden Glaspulvers nach einem der Ansprüche 1 bis 14 in Nahrungsmitteln.
- 21The use of an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 14 in cleaning materials. Utilisation d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 14 dans des détergents. Verwendung eines entzündungshemmend und wundheilend wirkenden Glaspulvers nach einem der Ansprüche 1 bis 14 in Reinigungsmitteln.
- 22The use of an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 14 in anti-transpirants. Utilisation d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 14 dans des antitranspirants. Verwendung eines entzündungshemmend und wundheilend wirkende Glaspulvers nach einem der Ansprüche 1 bis 14 in Anti-Transpiranten.
- 23The use of an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 14 in paints and lacquers. Utilisation d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 14 dans des peintures et des vernis. Verwendung eines entzündungshemmend und wundheilend wirkenden Glaspulvers nach einem der Ansprüche 1 bis 14 in Farben und Lacken.
- 24The use of an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 14 in products for treating skin irritations, acute and chronic wounds. Utilisation d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 14 dans des produits pour le traitement des irritations cutanées et des plaies aiguës et chroniques. Verwendung eines entzündungshemmend und wundheilend wirkenden Glaspulvers nach einem der Ansprüche 1 bis 14 in Produkten zur . Behandlung von Hautirritationen, akuten und chronischen Wunden.
- 25A method for producing an anti-inflammatory and wound-healing glass powder according to one of the claims 1 to 14, comprising the following steps:25.1 a glass is molten from raw materials;25.2 the molten glass is further processed into ribbons;25.3 the ribbons are ground into glass powder, with the size of the glass particles of the glass powder being on average < 100 µm, preferably < 50 µm, more preferably < 20 µm. Procédé de fabrication d'une poudre de verre ayant un effet anti-inflammatoire et cicatrisant selon l'une quelconque des revendications 1 à 14, comprenant les étapes suivantes : 25.1 fusion des matières premières pour obtenir un verre25.2 traitement du verre fondu pour obtenir des rubans25.3 broyage des rubans pour obtenir de la poudre de verre, la taille des particules de verre de la poudre de verre étant en moyenne < 100 µm, de préférence < 50 µm et en particulier < 20 µm. Verfahren zur Herstellung eines entzündungshemmenden und wundheilend wirkenden Glaspulvers nach einem der Ansprüche 1 bis 14 umfassend die folgenden Schritte: 25.1 es wird aus Rohstoffen ein Glas erschmolzen25.2 das erschmolzene Glas wird zu Ribbons weiterverarbeitet25.3 die Ribbons werden zu Glaspulver gemahlen, wobei die Größe der Glaspartikel des Glaspulvers im Mittel < 100 µm, bevorzugt < 50 µm, besonders bevorzugt < 20 µm ist
Independent claims25
60 paragraphs in 1 section, as filed
The invention relates to an antimicrobial, anti-inflammatory, wound healing glass powder.
Anti-inflammatory wound healing glasses have become known from the following publications:<ul><li>US 5,834,008</li><li>WO 00/15167</li><li>WO 00/66086</li></ul>
The anti-inflammatory and wound-healing glasses or glass powders from such glasses comprise, according to the prior art, all bioactive glasses.
In the case of the bioactive glasses known from the abovementioned publications with an anti-inflammatory effect, the bioactive glass has a significant phosphorus content of> 1% by weight.
The essential properties of bioactive glass are known to a person skilled in the art and are described, for example, in US Pat. No. 5,074,916. Thereafter, bioactive glass differs from conventional lime-sodium silicate glasses by binding living tissue.
Bioactive glass refers to a glass that forms a solid bond with body tissue, forming a hydroxyl apatite layer.
A disadvantage of the bioactive glasses is the high phosphorus content, which leads to production problems when the glass is melted.
Furthermore, because of their low hydrolytic stability, the bioactive glasses are only very limited for grinding in aqueous media.
Ceramics and glassy precursors are known from EP 0 425 927.
The object of the invention is thus to provide an anti-inflammatory and wound-healing glass powder which is easier to produce, is toxicologically harmless and environmentally friendly in comparison to the bioactive glasses or glass powders from such glasses.
A glass powder with a particle size <1 mm, preferably <500 μm, or a glass fiber with a diameter of <1 mm, preferably <500 μm, is understood as meaning a powder comprising a plurality of glass particles of any shape, including glass fibers.
Furthermore, the glass powder compositions should comprise glass compositions which have a skin-soothing, anti-inflammatory and healing effect against skin irritations, skin irritations, acute as well as chronic wounds or inflammations, but which are toxicologically harmless in contact with humans and in particular also suitable for consumption.
According to the invention, the object is achieved by an anti-inflammatory and wound-healing glass powder according to one of claims 1, 4 or 7. The glass of the glass powder can preferably be 20-80% by weight of SiO.sub.2<sub>2</sub>, 0-40% by weight of Na<sub>2</sub>O, 0-40% by weight of K<sub>2</sub>O, 0-40% by weight of Li<sub>2</sub>O, 0-40% by weight of CaO, 0-40% by weight of MgO, 0-40% by weight of Al<sub>2</sub>O<sub>3</sub>, 0% by weight of P<sub>2</sub>O<sub>5</sub>, 0-40% by weight of B<sub>2</sub>O<sub>3</sub> include. The glass can also preferably contain 0-30% by weight of XFy, where X can be Li, Na, K, Be, Mg, Ca and y is 1 or y = 2, and / or 0-10 wt. % XJ<sub>y</sub>, Where X can be Li, Na, K, Be, Mg, Ca and y is 1 or y = 2. The sum is preferably Na<sub>2</sub>O + K<sub>2</sub>O + Li<sub>2</sub>O + CaO + MgO 15 to 80% by weight. More preferably, the sum is Na<sub>2</sub>O + K<sub>2</sub>O + Li<sub>2</sub>O 5 to 50% by weight. Alternatively, the sum + CaO + MgO can be 5 to 50% by weight.
The glass powder according to the invention can be produced on a large industrial scale by standard methods, since the glass composition can be melted on a large industrial scale.
The glass powders according to the invention can be added to products. Because of their hydrolytic stability, the glass compositions can also be ground to glass powders in aqueous grinding media.
In addition to the anti-inflammatory effect, the glass powders also have antimicrobial properties.
The glasses, which are ground to glass powders, can be made very pure. The glass powders are then toxicologically safe and suitable for consumption. The burden of heavy metals is low. Thus, the maximum concentration in the range of cosmetic products is preferably Pb <20 ppm, Cd <5 ppm, As <5 ppm, Sb <10 ppm, Hg <1 ppm, Ni <10 ppm.
By means of the additional antimicrobial effect, a preservation of products itself can be achieved or an antimicrobial effect can be achieved externally. Areas of application include, for example, cosmetic products, deodorant products, foodstuffs, paints, varnishes, plasters, paper sanitary products, medical products and cleaners.
For certain fields of application deliberately added amounts of heavy metals such as Ag, Cu, Zn are advantageous for achieving a synergistically enhanced antimicrobial and anti-inflammatory effect.
Skin irritation plays an essential role in the cosmetic field. Therefore, it is advantageous if the flame-retardant and wound-healing glass powder is particularly skin-friendly.
A particular advantage of the glass powder according to the invention is that it comprises a glass which is suitable due to the melting and hot shaping behavior in order to be produced in corresponding large-scale plants.
Since the process temperatures or the viscosity of the glass is low, low-cost materials can be used in the melt and hot-shaping process.
In addition to the production by means of a melting process, alternative production methods are also conceivable via the sol-gel or reaction-sinter route.
Surprisingly, in the case of the glass powders according to the invention, the stated glass composition exhibits an anti-inflammatory and wound healing effect which can be extremely strong. The lower the mean particle size of the glass powder, the higher the anti-inflammatory and healing effect due to the increase in the reactive surface area of the glass.
Surprisingly, this anti-inflammatory and wound healing property is also found in glass powders comprising glasses which have a relatively high hydrolytic resistance as a semi-finished product. However, with a small particle size and with a large surface area, a drastic increase in reactivity is observed, resulting in an anti-inflammatory and healing effect due to the ion exchange described below.
In the glass powders according to the invention, alkalies of the glass are caused by reactions on the surface of the glass by H<sup>+</sup>Ions of the aqueous medium. The anti-inflammatory and curative action is based inter alia on a release of ions as well as on surface effects of the particles such as, for example, the surface charge and the antimicrobial effect of the glass powders on germs.
Glass powders with ion-exchangeable glasses according to the invention have an anti-inflammatory and wound healing effect in aqueous media by ion exchange between a metal ion, such as, for example, an alkali metal or alkaline earth metal ion and the H<sup>+</sup>(Osmotic pressure, influencing metabolic processes of the cells). The ground glass powders with particles of small particle size and large surface area show a drastic increase in reactivity, which results in a strong anti-inflammatory and wound-healing effect due to the already described ion exchange Effect. The reason for this is the exchange of ions which can have an anti-inflammatory effect, for example potassium. The anti-inflammatory action of the glass powders is surprising for the skilled worker since the glass compositions are largely inert in the ungrounded state. By milling such a largely inert composition, it is possible to achieve the liberation of ions such as, for example, K in the ground glass powder which have an anti-inflammatory effect on the epidermis. Such anti-inflammatory properties have always been attributed, in the prior art, to powders of reactive glasses having a phosphorus content of more than 1% by weight, since the formation of hydroxide-apatite layers has always been regarded as necessary for the bioactive and anti-inflammatory action.
With the aid of milling processes, the glass compositions can be ground to glass powders with particle sizes <100 μm. Particle sizes <50 μm or 20 μm have proven to be expedient. Particularly suitable are particle sizes <10 μm as well as less than 5 μm. Particle sizes <2 μm have been found to be particularly suitable.
The grinding process can be carried out both dryly and with aqueous and non-aqueous grinding media.
Mixtures of different glass powders from the composition range with different compositions and sizes are possible to combine certain effects.
Depending on the particle size, concentration and composition of the powder, pH values of up to 13 are achieved.
Mixtures of glass powders with different compositions and grain sizes can be synergistically combined to adjust specific properties of the individual glass powders. Thus, for example, it is possible to control the anti-inflammatory and curative action of the glass powder by the particle size.
The glass of the glass powder contains SiO<sub>2</sub> As a network former, preferably between 35 and 80% by weight. At low concentrations, the hydrolytic resistance decreases strongly, so that grinding in aqueous media is no longer ensured without significant dissolution of the glass.
N / A<sub>2</sub>O is used as a flux during the melting of the glass. At concentrations below 5%, the melting behavior is adversely affected. Moreover, the necessary mechanism of the ion exchange is no longer sufficient to achieve an anti-inflammatory and wound healing effect. At higher Na<sub>2</sub>O concentrations as 30% by weight is a deterioration in chemical resistance or hydrolytic resistance, in particular in conjunction with a decrease in SiO<sub>2</sub>Share.
Alkali and alkaline earth oxides can be used, in particular, in order to increase ion exchange and thus to enhance the anti-inflammatory and curative action.
The amount of Al<sub>2</sub>O<sub>3</sub> Can be added up to a maximum of 8% by weight to increase the chemical stability of the crystallization stability and the control of the antimicrobial effect.
B<sub>2</sub>O<sub>3</sub> Acts as a network former and can also serve to control the anti-inflammatory and healing effects.
ZnO is an essential component for the thermoforming properties of the glass. It improves the crystallization stability and increases the surface tension. In addition, it can support the anti-inflammatory and healing effect. At low SiO<sub>2</sub>It increases the crystallization stability. To achieve an anti-inflammatory and wound-healing effect, up to 8% by weight of ZnO can be present. A preferred embodiment contains <4% by weight of ZnO or <2% by weight. Versions with <1% by weight or 0.5% by weight or <0.1% by weight are particularly preferred.
In order to enhance the anti-inflammatory and curative action of the base glass, AgO, CuO can be added as active additives.
The glass according to the invention does not produce any skin-irritating effects.
By a combination of the pH-effect and the Ag, Cu or Zn-discharge a considerable increase of the anti-inflammatory and wound healing effect as well as the additional antimicrobial effect can be obtained, which goes beyond the sum of the individual effects significantly. The concentration of Ag, Cu, Zn-ions released into the product can be clearly below 1 ppm.
The introduction of Ag, Cu, Zn can either take place in the melt by means of corresponding salts or else by ion exchange of the glass after the melt.
In order to achieve color effects, individual or else several color-imparting components, such as Fe<sub>2</sub>O<sub>3</sub>, CoO, CuO, V<sub>2</sub>O<sub>5</sub>, Cr<sub>2</sub>O<sub>5</sub> In a total concentration of less than 4% by weight, preferably less than 1% by weight.
Glass powders with glasses within the claimed composition range meet all requirements for use in the areas of paper hygiene, cosmetics, paints, varnishes, cleaning products, medical products, cosmetic applications, food additives as well as use in deodorant products, anti-perspirants and products for the treatment of skin irritations And chronic wounds.
A property of the glass powder is the surprisingly proven skin tolerance, which is also given at high concentrations with high pH values.
The glass powder can be used in any suitable form. Mixtures of different glass powders from the composition range with different compositions are also possible. The mixture with other glass powders is also possible to combine certain effects.
Depending on the application area, components such as fluorine can be added to the glass up to concentrations of a total of 5% by weight.
The glass described in this invention from which the glass powder according to the invention is obtained by grinding is not or hardly water-soluble. The glass powder acts primarily by ion exchange, which is associated with a surface reaction, pH increase and metal ion release.
Surprisingly, the glass powders according to the invention show a higher anti-inflammatory and healing effect than the group of bioactive glasses described in the prior art or glass powders made from such glasses.
The invention is to be described below with reference to the exemplary embodiments and figures.
Show it:<dl id="dl0001" compact="compact"><dt>FIG</dt><dd>The regeneration of the barrier function of the epidermis after pre-injury.</dd></dl>
EXEMPLARY EMBODIMENTS
From the raw materials, the glass was melted in a silica glass crucible, which was then processed into ribbons. The ribbons were further processed by means of dry grinding to form powder having a particle size d.sub.50 = 4 .mu.m.
Table 2 shows the compositions and properties of glasses which can be ground to the glass powders according to the invention. The compositions refer to synthesis values in weight percent on oxide basis.<tables id="tabl0001" num="0001"><table frame="all"><title><u>Table 1:</u></title><tgroup cols="4" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="14mm" colsep="1" /><colspec colnum="2" colname="col2" colwidth="12mm" colsep="1" /><colspec colnum="3" colname="col3" colwidth="12mm" colsep="1" /><colspec colnum="4" colname="col4" colwidth="12mm" colsep="1" /><thead><row><entry namest="col1" nameend="col1" align="center" valign="top" /><entry namest="col2" nameend="col2" align="center" valign="top">V.1</entry><entry namest="col3" nameend="col3" align="center" valign="top">V.2</entry><entry namest="col4" nameend="col4" align="center" valign="top">V.3</entry></row></thead><tbody><row><entry namest="col1" nameend="col1" align="left" valign="top">SiO<sub>2</sub></entry><entry namest="col2" nameend="col2" align="left" valign="top">45.0</entry><entry namest="col3" nameend="col3" align="left" valign="top">58.2</entry><entry namest="col4" nameend="col4" align="left" valign="top">35.0</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">Al<sub>2</sub>O<sub>3</sub></entry><entry namest="col2" nameend="col2" align="left" valign="top" /><entry namest="col3" nameend="col3" align="left" valign="top" /><entry namest="col4" nameend="col4" align="left" valign="top" /></row><row><entry namest="col1" nameend="col1" align="left" valign="top">CaO</entry><entry namest="col2" nameend="col2" align="left" valign="top">24.5</entry><entry namest="col3" nameend="col3" align="left" valign="top">32.6</entry><entry namest="col4" nameend="col4" align="left" valign="top">29.5</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">MgO</entry><entry namest="col2" nameend="col2" align="left" valign="top" /><entry namest="col3" nameend="col3" align="left" valign="top" /><entry namest="col4" nameend="col4" align="left" valign="top" /></row><row><entry namest="col1" nameend="col1" align="left" valign="top">Fe<sub>2</sub>O<sub>3</sub></entry><entry namest="col2" nameend="col2" align="left" valign="top" /><entry namest="col3" nameend="col3" align="left" valign="top" /><entry namest="col4" nameend="col4" align="left" valign="top" /></row><row><entry namest="col1" nameend="col1" align="left" valign="top">N / A<sub>2</sub>O</entry><entry namest="col2" nameend="col2" align="left" valign="top">24.5</entry><entry namest="col3" nameend="col3" align="left" valign="top" /><entry namest="col4" nameend="col4" align="left" valign="top">29.5</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">K<sub>2</sub>O</entry><entry namest="col2" nameend="col2" align="left" valign="top" /><entry namest="col3" nameend="col3" align="left" valign="top" /><entry namest="col4" nameend="col4" align="left" valign="top" /></row><row><entry namest="col1" nameend="col1" align="left" valign="top">P<sub>2</sub>O<sub>5</sub></entry><entry namest="col2" nameend="col2" align="left" valign="top">6.0</entry><entry namest="col3" nameend="col3" align="left" valign="top">9.2</entry><entry namest="col4" nameend="col4" align="left" valign="top">6.0</entry></row></tbody></tgroup></table></tables><tables id="tabl0002" num="0002"><table frame="all"><title>Table 2:</title><tgroup cols="8" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="9mm" colsep="1" /><colspec colnum="2" colname="col2" colwidth="33mm" colsep="1" /><colspec colnum="3" colname="col3" colwidth="34mm" colsep="1" /><colspec colnum="4" colname="col4" colwidth="34mm" colsep="1" /><colspec colnum="5" colname="col5" colwidth="34mm" colsep="1" /><colspec colnum="6" colname="col6" colwidth="34mm" colsep="1" /><colspec colnum="7" colname="col7" colwidth="34mm" colsep="1" /><colspec colnum="8" colname="col8" colwidth="34mm" colsep="1" /><thead><row><entry namest="col1" nameend="col1" align="center" valign="top" /><entry namest="col2" nameend="col2" align="center" valign="top"><b>FIG</b> 1</entry><entry namest="col3" nameend="col3" align="center" valign="top"><b>EXAMPLE 2</b></entry><entry namest="col4" nameend="col4" align="center" valign="top"><b>EXAMPLE 3</b></entry><entry namest="col5" nameend="col5" align="center" valign="top"><b>EXAMPLE 4</b></entry><entry namest="col6" nameend="col6" align="center" valign="top"><b>EXAMPLE 5</b></entry><entry namest="col7" nameend="col7" align="center" valign="top"><b>EXAMPLE 6</b></entry><entry namest="col8" nameend="col8" align="center" valign="top"><b>EXAMPLE 7</b></entry></row></thead><tbody><row><entry namest="col1" nameend="col1" align="left" valign="top">SiO<sub>2</sub></entry><entry namest="col2" nameend="col2" valign="top" align="char" char="." charoff="53">71.2</entry><entry namest="col3" nameend="col3" valign="top" align="char" char="." charoff="53">45.0</entry><entry namest="col4" nameend="col4" valign="top" align="char" char="." charoff="53">72.0</entry><entry namest="col5" nameend="col5" valign="top" align="char" char="." charoff="53">60.0</entry><entry namest="col6" nameend="col6" valign="top" align="char" char="." charoff="53">48.0</entry><entry namest="col7" nameend="col7" valign="top" align="char" char="." charoff="53">45.0</entry><entry namest="col8" nameend="col8" valign="top" align="char" char="." charoff="53">45.0</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">B<sub>2</sub>O<sub>3</sub></entry><entry namest="col2" nameend="col2" valign="top" align="char" char="." charoff="53" /><entry namest="col3" nameend="col3" valign="top" align="char" char="." charoff="53" /><entry namest="col4" nameend="col4" valign="top" align="char" char="." charoff="53" /><entry namest="col5" nameend="col5" valign="top" align="char" char="." charoff="53" /><entry namest="col6" nameend="col6" valign="top" align="char" char="." charoff="53" /><entry namest="col7" nameend="col7" valign="top" align="char" char="." charoff="53" /><entry namest="col8" nameend="col8" valign="top" align="char" char="." charoff="53">10.0</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">Al<sub>2</sub>O<sub>3</sub></entry><entry namest="col2" nameend="col2" valign="top" align="char" char="." charoff="53">0.35</entry><entry namest="col3" nameend="col3" valign="top" align="char" char="." charoff="53" /><entry namest="col4" nameend="col4" valign="top" align="char" char="." charoff="53" /><entry namest="col5" nameend="col5" valign="top" align="char" char="." charoff="53" /><entry namest="col6" nameend="col6" valign="top" align="char" char="." charoff="53" /><entry namest="col7" nameend="col7" valign="top" align="char" char="." charoff="53" /><entry namest="col8" nameend="col8" valign="top" align="char" char="." charoff="53" /></row><row><entry namest="col1" nameend="col1" align="left" valign="top">P<sub>2</sub>O<sub>5</sub></entry><entry namest="col2" nameend="col2" valign="top" align="char" char="." charoff="53" /><entry namest="col3" nameend="col3" valign="top" align="char" char="." charoff="53" /><entry namest="col4" nameend="col4" valign="top" align="char" char="." charoff="53" /><entry namest="col5" nameend="col5" valign="top" align="char" char="." charoff="53" /><entry namest="col6" nameend="col6" valign="top" align="char" char="." charoff="53" /><entry namest="col7" nameend="col7" valign="top" align="char" char="." charoff="53">1.0</entry><entry namest="col8" nameend="col8" valign="top" align="char" char="." charoff="53" /></row><row><entry namest="col1" nameend="col1" align="left" valign="top">CaO</entry><entry namest="col2" nameend="col2" valign="top" align="char" char="." charoff="53">9.9</entry><entry namest="col3" nameend="col3" valign="top" align="char" char="." charoff="53">24.5</entry><entry namest="col4" nameend="col4" valign="top" align="char" char="." charoff="53">9.6</entry><entry namest="col5" nameend="col5" valign="top" align="char" char="." charoff="53">20.0</entry><entry namest="col6" nameend="col6" valign="top" align="char" char="." charoff="53">20.0</entry><entry namest="col7" nameend="col7" valign="top" align="char" char="." charoff="53">27.5</entry><entry namest="col8" nameend="col8" valign="top" align="char" char="." charoff="53">25.0</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">MgO</entry><entry namest="col2" nameend="col2" valign="top" align="char" char="." charoff="53">4,2</entry><entry namest="col3" nameend="col3" valign="top" align="char" char="." charoff="53" /><entry namest="col4" nameend="col4" valign="top" align="char" char="." charoff="53">4.0</entry><entry namest="col5" nameend="col5" valign="top" align="char" char="." charoff="53" /><entry namest="col6" nameend="col6" valign="top" align="char" char="." charoff="53">10.0</entry><entry namest="col7" nameend="col7" valign="top" align="char" char="." charoff="53" /><entry namest="col8" nameend="col8" valign="top" align="char" char="." charoff="53" /></row><row><entry namest="col1" nameend="col1" align="left" valign="top">Fe<sub>2</sub>O<sub>3</sub></entry><entry namest="col2" nameend="col2" valign="top" align="char" char="." charoff="53">0.1</entry><entry namest="col3" nameend="col3" valign="top" align="char" char="." charoff="53" /><entry namest="col4" nameend="col4" valign="top" align="char" char="." charoff="53" /><entry namest="col5" nameend="col5" valign="top" align="char" char="." charoff="53" /><entry namest="col6" nameend="col6" valign="top" align="char" char="." charoff="53" /><entry namest="col7" nameend="col7" valign="top" align="char" char="." charoff="53" /><entry namest="col8" nameend="col8" valign="top" align="char" char="." charoff="53" /></row><row><entry namest="col1" nameend="col1" align="left" valign="top">Li<sub>2</sub>O</entry><entry namest="col2" nameend="col2" valign="top" align="char" char="." charoff="53" /><entry namest="col3" nameend="col3" valign="top" align="char" char="." charoff="53" /><entry namest="col4" nameend="col4" valign="top" align="char" char="." charoff="53" /><entry namest="col5" nameend="col5" valign="top" align="char" char="." charoff="53" /><entry namest="col6" nameend="col6" valign="top" align="char" char="." charoff="53">2.0</entry><entry namest="col7" nameend="col7" valign="top" align="char" char="." charoff="53" /><entry namest="col8" nameend="col8" valign="top" align="char" char="." charoff="53" /></row><row><entry namest="col1" nameend="col1" align="left" valign="top">N / A<sub>2</sub>O</entry><entry namest="col2" nameend="col2" valign="top" align="char" char="." charoff="53">14.2</entry><entry namest="col3" nameend="col3" valign="top" align="char" char="." charoff="53">30.5</entry><entry namest="col4" nameend="col4" valign="top" align="char" char="." charoff="53">14.4</entry><entry namest="col5" nameend="col5" valign="top" align="char" char="." charoff="53">20.0</entry><entry namest="col6" nameend="col6" valign="top" align="char" char="." charoff="53">10.0</entry><entry namest="col7" nameend="col7" valign="top" align="char" char="." charoff="53">27.5</entry><entry namest="col8" nameend="col8" valign="top" align="char" char="." charoff="53">15.0</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top">K<sub>2</sub>O</entry><entry namest="col2" nameend="col2" valign="top" align="char" char="." charoff="53">0.05</entry><entry namest="col3" nameend="col3" valign="top" align="char" char="." charoff="53" /><entry namest="col4" nameend="col4" valign="top" align="char" char="." charoff="53" /><entry namest="col5" nameend="col5" valign="top" align="char" char="." charoff="53" /><entry namest="col6" nameend="col6" valign="top" align="char" char="." charoff="53">10.0</entry><entry namest="col7" nameend="col7" valign="top" align="char" char="." charoff="53" /><entry namest="col8" nameend="col8" valign="top" align="char" char="." charoff="53">5.0</entry></row></tbody></tgroup></table></tables>
Table 1 shows comparative examples of bioactive glasses V1, V2 and V3. Table 2 shows exemplary embodiments A1 to A7.
Particularly simple to manufacture and industrially available, since large-scale systems can be melted Glasses comprising the following components, the data being based on the oxide by weight:
SiO<sub>2</sub>: 68-75% by weight, Na<sub>2</sub>O: 10-20% by weight, Al<sub>2</sub>O<sub>3</sub>: 0-3% by weight, CaO: 5-15% by weight, MgO: 0-10% by weight. Glasses of this type show an anti-inflammatory and healing effect after the grinding. This is surprising for the person skilled in the art, since glasses with a phosphorus content of less than 1% by weight, based on oxide, for example lime-soda-lime glasses, are largely inactive as glass. An anti-inflammatory effect was only attributed to phosphorus-containing glasses with a phosphorus content> 1% by weight, since these glasses are considered to be very reactive.
All glasses, in particular the suitable glasses in the composition indicated above, can have trace elements and / or customary refining agents in conventional amounts. Trace elements are, for example, impurities contained in the glass, such as Fe<sub>2</sub>O<sub>3</sub> or K<sub>2</sub>O; Conventional refining agents As<sub>2</sub>O<sub>3</sub>, Sb<sub>2</sub>O<sub>3</sub>. The anti-inflammatory and healing effects which are superior to the bioactive glasses are shown in studies in mice. Experiments were carried out with one mouse each at three measuring points. The active substances A.1, V.1, V.2 and V.3 investigated as glass powders were applied to a quantity of 10% by weight in a DAC base cream. For comparison with the DAC cream provided with an active substance, a DAC base cream without active ingredient was also applied.
FIG. 1 shows the temporal course of the repair of a superficial wound, ie the regeneration of the barrier function of the epidermis, measured by transepidermal water loss. The superficial wound was obtained by a pre-treatment with tape stripping. Tape stripping is understood to mean damage to the uppermost layers of hair by the application and removal of adhesive strips.
FIG. 1 shows that the regeneration of the barrier function of the skin after 24 hours with a glass powder with glass composition according to the invention is approx. 10% better than with the bioactive glass powder V.1. The bioactive glass powders V.2 and V.3 as well as the DAC cream without active substance as comparison samples show an even lower regeneration of the barrier function. The comparative tests clearly show the anti-inflammatory, curative action of the glass powders according to the invention with the stated glass composition superior to the bioactive glass powders. Furthermore, the glass powders according to the invention also have an antimicrobial effect. This is according to Europ. Pharmacopoeia (3rd edition) for the embodiment A1 with a particle size d 50 of 4 μm is given in Table 3.<tables id="tabl0003" num="0003"><table frame="all"><title><u>Table 3:</u></title><tgroup cols="6" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="16mm" colsep="1" /><colspec colnum="2" colname="col2" colwidth="16mm" colsep="1" /><colspec colnum="3" colname="col3" colwidth="26mm" colsep="1" /><colspec colnum="4" colname="col4" colwidth="20mm" colsep="1" /><colspec colnum="5" colname="col5" colwidth="22mm" colsep="1" /><colspec colnum="6" colname="col6" colwidth="18mm" colsep="1" /><thead><row><entry namest="col1" nameend="col1" align="left" valign="top" /><entry namest="col2" nameend="col2" align="left" valign="top"><b>E. coli</b></entry><entry namest="col3" nameend="col3" align="left" valign="top"><b>P. aeruginosa</b></entry><entry namest="col4" nameend="col4" align="left" valign="top"><b>S. aureus</b></entry><entry namest="col5" nameend="col5" align="left" valign="top"><b>C. albicans</b></entry><entry namest="col6" nameend="col6" align="left" valign="top"><b>A. niger</b></entry></row></thead><tbody><row><entry namest="col1" nameend="col1" align="left" valign="top"><b>start</b></entry><entry namest="col2" nameend="col2" align="left" valign="top">290000</entry><entry namest="col3" nameend="col3" align="left" valign="top">270000</entry><entry namest="col4" nameend="col4" align="left" valign="top">250000</entry><entry namest="col5" nameend="col5" align="left" valign="top">300000</entry><entry namest="col6" nameend="col6" align="left" valign="top">250000</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top"><b>2 days</b></entry><entry namest="col2" nameend="col2" align="left" valign="top">900</entry><entry namest="col3" nameend="col3" align="left" valign="top">1800</entry><entry namest="col4" nameend="col4" align="left" valign="top">800</entry><entry namest="col5" nameend="col5" align="left" valign="top"><100</entry><entry namest="col6" nameend="col6" align="left" valign="top">2000</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top"><b>7 days</b></entry><entry namest="col2" nameend="col2" align="left" valign="top"><100</entry><entry namest="col3" nameend="col3" align="left" valign="top">200</entry><entry namest="col4" nameend="col4" align="left" valign="top"><100</entry><entry namest="col5" nameend="col5" align="left" valign="top">0</entry><entry namest="col6" nameend="col6" align="left" valign="top">2000</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top"><b>14 days</b></entry><entry namest="col2" nameend="col2" align="left" valign="top">0</entry><entry namest="col3" nameend="col3" align="left" valign="top">0</entry><entry namest="col4" nameend="col4" align="left" valign="top">0</entry><entry namest="col5" nameend="col5" align="left" valign="top">0</entry><entry namest="col6" nameend="col6" align="left" valign="top">0</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top"><b>21 days</b></entry><entry namest="col2" nameend="col2" align="left" valign="top">0</entry><entry namest="col3" nameend="col3" align="left" valign="top">0</entry><entry namest="col4" nameend="col4" align="left" valign="top">0</entry><entry namest="col5" nameend="col5" align="left" valign="top">0</entry><entry namest="col6" nameend="col6" align="left" valign="top">0</entry></row><row><entry namest="col1" nameend="col1" align="left" valign="top"><b>28 days</b></entry><entry namest="col2" nameend="col2" align="left" valign="top">0</entry><entry namest="col3" nameend="col3" align="left" valign="top">0</entry><entry namest="col4" nameend="col4" align="left" valign="top">0</entry><entry namest="col5" nameend="col5" align="left" valign="top">0</entry><entry namest="col6" nameend="col6" align="left" valign="top">0</entry></row></tbody></tgroup></table></tables>
The glass powders which are inflammatory and wound healing can be used as a food additive, in cosmetic products and deodorant products, in particular for the reduction of skin irritations, but not limited to, in medical products, in particular products for wound care and treatment, plastics and polymers, paper hygiene, paints, lacquers and in Cleaning agents.
1 sheet
Sheet 1
Every citation, both waysCites: the store holds 5 of 6
| Document | Relation | Office |
|---|---|---|
| EP0425927A | Cites | European Patent Office (EPO) |
| EP0921105A | Cites | European Patent Office (EPO) |
| WO0076486A | Cites | World Intellectual Property Organization (WIPO) |
| WO9621628A | Cites | World Intellectual Property Organization (WIPO) |
| JP7025635A | Cites | Japan |
21 members in 6 offices
Priority claims24
| Document | Office | Kind | Date |
|---|---|---|---|
| 10141116 | Germany | A | |
| 10141116 | Germany | A | |
| 10141116 | Germany | – | |
| 10156577 | Germany | A | |
| 10156577 | Germany | A | |
| 10156577 | Germany | – | |
| 10213630 | Germany | A | |
| 10213630 | Germany | A | |
| 10213630 | Germany | – | |
| 10213632 | Germany | A | |
| 10213632 | Germany | A | |
| 10213632 | Germany | – | |
| 0209220 | European Patent Office (EPO) | W | |
| 0209220 | European Patent Office (EPO) | W | |
| 10141116 | – | – | – |
| 10156577 | – | – | – |
| 10213630 | – | – | – |
| 10213632 | – | – | – |
| DE2001141116 | – | – | – |
| DE2001156577 | – | – | – |
| DE2002113630 | – | – | – |
| DE2002113632 | – | – | – |
| EP2002009220 | – | – | – |
| WO2002EP09220 | – | – | – |
Members21
| Document | Office | Kind | |
|---|---|---|---|
| WO03018496A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO03018498A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO03018499A2 | World Intellectual Property Organization (WIPO) | A2 | |
| DE10213630A1 | Germany | A1 | |
| DE10213632A1 | Germany | A1 | |
| WO03018499A3 | World Intellectual Property Organization (WIPO) | A3 | |
| DE10156577A1 | Germany | A1 | |
| EP1419118A1 | European Patent Office (EPO) | A1 | |
| DE10293768D2 | Germany | D2 | |
| US2004253321A1 | United States of America | A1 | |
| JP2005501113A | Japan | A | |
| US2005064193A1 | United States of America | A1 | |
| DE10293767D2 | Germany | D2 | |
| EP1419118B1This record | European Patent Office (EPO) | B1 | |
| AT332879T | Austria | T | |
| ATE332879T1 | Austria | T1 | |
| DE50207515D1 | Germany | D1 | |
| US7166549B2 | United States of America | B2 | |
| US7709027B2 | United States of America | B2 | |
| DE10293768B4 | Germany | B4 | |
| DE10293767B4 | Germany | B4 |
52 legal events, as 5 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent expired after termination of 20 yearsExpiredPE20 | PE20 | GB | |
| Patent ceasedCeasedPL | PL | CH | |
| Expiry of rightR071 | R071 | DE | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Be: lapsedLapsedBERE | BERE | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Change of the address of the representativeISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH)PCAR | PCAR | CH | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Fr: translation not filedEN | EN | EP | |
| European patents designating ireland treated as always having been voidFD4D | FD4D | IE | |
| Gb: translation of ep patent filed (gb section 77(6)(a)/1977)GBT | GBT | EP | |
| Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents actLapsedNLV1 | NLV1 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| New agentNV | NV | CH | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedLANGUAGE OF EP DOCUMENT: GERMANFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedNOT ENGLISHFG4D | FG4D | GB | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1419118
- Publication, DOCDB
- 1419118
- Publication, EPODOC
- EP1419118
- Application
- 2772168
- Application, DOCDB
- 02772168
- Application, EPODOC
- EP20020772168
Titles3
- German
- ANTIMIKROBIELLES, ENTZÜNDUNGSHEMMENDES, WUNDHEILENDES GLASPULVER UND DESSEN VERWENDUNG
- English
- ANTIMICROBIAL, ANTI-INFLAMMATORY, WOUND-HEALING GLASS POWDER AND USE THEREOF
- French
- POUDRE DE VERRE ANTIMICROBIENNE, ANTI-INFLAMMATOIRE, CICATRISANTE ET UTILISATION
Classification
- CPC, 17
- C03C3/062
- A61P17/02
- A61P29/00
- C03C3/076
- A61P31/04
- C03C3/095
- A61P31/10
- C03C3/11
- C03C4/0007
- C03C12/00
- C03C2204/02
- C08K3/40
- C09D5/14
- C09D7/61
- C09D7/67
- C09D7/68
- C09D7/69
- IPC, 34
- C03C3 076
- C03C3 095
- C03C12 00
- C03C4 00
- C03C3 11
- C03C3 062
- A23L1 30
- A61K8 00
- A61K8 19
- A61K8 25
- A61K8 26
- A61K8 27
- A61K33 00
- A61K33 08
- A61K33 22
- A61K33 30
- A61K33 42
- A61P17 02
- A61P29 00
- A61P31 04
- A61P31 10
- A61Q15 00
- A61Q19 00
- A61Q19 10
- C03C3 078
- C03C3 083
- C03C3 085
- C03C3 087
- C03C3 089
- C03C3 091
- C03C3 093
- C09D5 14
- C09D7 12
- C09D201 00
Designated states24
- Contracting states, 24
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czechia
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Sweden
- Slovakia
- Türkiye